<DOC>
	<DOC>NCT00808678</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.</brief_summary>
	<brief_title>Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium</brief_title>
	<detailed_description />
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1. A condition of general good health 2. BMI 19 to 29 1. Currently enrolled in another clinical study 2. Females who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Adverse Events</keyword>
</DOC>